Cost Utility of Vaccination Against COVID-19 in Brazil

Página do item simplificado
dc.contributor.authorFernandes, Ricardo Ribeiro Alves
dc.contributor.authorSantos, Marisa da Silva
dc.contributor.authorMagliano, Carlos Alberto da Silva
dc.contributor.authorTura, Bernardo Rangel
dc.contributor.authorMacedo, Luana Schroeder Damico
dc.contributor.authorPadila, Matheus Piccin
dc.contributor.authorFrança, Ana Cláudia Wekmuller
dc.contributor.authorBraga, Andressa Araujo
dc.date.accessioned2024-02-01T13:46:42Z
dc.date.available2024-02-01T13:46:42Z
dc.date.issued2022
dc.description.abstractObjectives: The objective of this study was to evaluate the cost-utility of the Oxford, CoronaVac, and Janssen COVID-19 vaccines from the perspective of the Brazilian public health system. Methods: A total of 3 microsimulation models were constructed with individual data to evaluate the 3 vaccines. The simulation contains 7 transition states that are related to the natural history of the disease. The model with a daily cycle has a time horizon of 1 year and uses data from 289 days of the pandemic. The analysis was conducted from the perspective of the Brazilian public health system considering direct medical costs. For the model inputs, outpatient and hospital databases were used with information on treated patients stratified by age. Information on mortality was also stratified based on patients' age in the mortality database (SIM). The efficacy of vaccines to reduce the likelihood of patients becoming ill was evaluated independently for each vaccine. Information on the quality of life of patients in outpatient or hospital treatment and the sequelae resulting from the disease were extracted from the literature. The main outcome of the analysis was quality-adjusted life-years (QALYs). Results: The vaccines showed incremental cost-utility ratios ranging from R$-23 161.3/QALY (Oxford) to R$17 757.85/QALY (CoronaVac). The older the population, the lower was the incremental cost-utility ratio. Given a willingness-to-pay threshold of R$17 586/QALY, all the vaccines were considered cost-effective in the probabilistic sensitivity analysis. Conclusions: The results of the analysis by age group can help in the preparation of a vaccination prioritization plan.
dc.identifier.citationFernandes RRA, Santos MDS, Magliano CADS, Tura BR, Macedo LSDN, Padila MP, França ACW, Braga AA. Cost Utility of Vaccination Against COVID-19 in Brazil. Value Health Reg Issues. 2022 Sep;31:18-24. doi: 10.1016/j.vhri.2022.01.009.
dc.identifier.otherDOI: 10.1016/j.vhri.2022.01.009
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/393
dc.language.isoen
dc.publisherValue Health Regional Issues
dc.subjectCOVID-19pt
dc.subjectHTApt
dc.subjectCost-utility analysispt
dc.subjectHealth technology assessmentpt
dc.subjectVaccinespt
dc.subject.meshVaccinationen
dc.subject.meshQuality of Lifeen
dc.subject.meshHumansen
dc.subject.meshCost-Benefit Analysisen
dc.subject.meshCOVID-19 / prevention & controlen
dc.subject.meshCOVID-19 Vaccines / therapeutic useen
dc.subject.meshBrazil / epidemiologyen
dc.titleCost Utility of Vaccination Against COVID-19 in Brazil
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Fernandes RRA et al_Value Health Reg Issues-.pdf
Tamanho:
827.34 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente
Produção Bibliográfica